Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Research
[키워드] Activation
acute respiratory syndrome
animal
Anti-spike
antibody
Antibody Response
approach
AZD1222
boost
booster dose
Booster vaccine
cell activation
cellular
ChAdOx1
ChAdOx1 nCoV-19
clinical trials
complement
coronavirus
coronavirus vaccine
dose
doses
evaluated
exploratory
facilitate
function
functional antibody responses
healthy
homologous
humoral
immunogenicity data
induce
Infection
Interim report
magnitude
multifunctional
natural killer
neutralizing antibody
neutralizing antibody titers
Open-label
outcome
phagocytosis
phase
Phase 3
Prevent
preventing infection
priming
Randomized controlled trial
receive
reported
Safe
SARS-CoV-2 vaccine
serology
subgroup
Support
T cell response
the vaccine
Trial
vaccination
Vaccine
viral spike protein
Viral vector
Volunteer
[DOI] 10.1038/s41591-020-01179-4 [Article Type] Research
[DOI] 10.1038/s41591-020-01179-4 [Article Type] Research